Advances in Mass Spectrometry for the Characterisation and Bioanalysis of Antibody-Drug Conjugates
Posted on April 18, 2017
Arnaud Delobel, PhD, R&D Director
Quality Assistance sa
www.quality-assistance.com
Abstract ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterisation as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
ADCs, antibody drug conjugate, Arnaud Delobel, bioanalytes, biotherapeutic proteins, Characterisation, cytotoxic drugs, cytotoxic small molecule, cytotoxic small molecules, DNA modifying agents, mass spectrometry, microtubule disrupting agents, monoclonal antibody, peptide, Quality Assistance, quantification in biological fluids, targeted anti-cancer agents
Related Products
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
